Galectin Therapeutics Presents Preclinical Data on the Treatment of Fatty Liver Disease and Fibrosis at EASL
12/16/2011 7:32:07 AM
NEWTON, Mass.--(BUSINESS WIRE)--Galectin Therapeutics Inc. (OTC: GALT), the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins, today announced that it presented a poster at the European Association for the Study of the Liver (EASL) Special Conference on Liver Transplantation in Lisbon, Portugal. The data show that galectin inhibitor candidate GR-MD-02 reversed fibrosis in mouse models of steatohepatitis and prevented collagen deposits in groups treated before fibrotic cells were present. The data suggest that patients with non-alcoholic steatohepatitis (NASH), also referred to as fatty liver disease, may benefit from galectin inhibition and that GR-MD-02 could drive in a reduction of steatosis, necrosis, inflammation and collagen deposits. Currently, liver transplantation is the only option for patients afflicted with liver fibrosis or cirrhosis, and many times the condition recurs in the patient’s new liver, creating the need for a safer and more efficacious treatment. The data presented provide promising evidence for advancing GR-MD-02 into clinical studies for the treatment of NASH.
comments powered by